Heart failure & cardiomyopathies
Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF
Authors' conclusion
Despite baseline demographic and clinical differences between LVEF cohorts in TRANSFORM-HF, there were no significant differences in the clinical end points with torsemide versus furosemide across the LVEF spectrum. There was a substantial risk for all-cause mortality and subsequent hospitalization independent of baseline LVEF.
Study context
- Population
- Patients hospitalized with heart failure (HF), stratified by left ventricular ejection fraction (LVEF): HFrEF (≤40%), HF with mildly reduced LVEF (41% to 49%), HFpEF (≥50%)had LVEF data
- Participants
- 2,635 patients
- Comparison
- Torsemide vs furosemide, by baseline LVEF
- Primary endpoint
- All-cause mortality or hospitalization; total hospitalizations; change in Kansas City Cardiomyopathy Questionnaire clinical summary score
- Follow-up
- 30 days and 12 months
Methodological detailssubgroup analysis by baseline LVEF
- Subgroup analysis by baseline LVEF
Primary result
As reported in the abstract
Torsemide vs furosemide treatment effect by LVEF subgroup
- No significant difference between torsemide and furosemide for mortality and hospitalization outcomes, irrespective of LVEF group
- No significant difference in change in KCCQ clinical summary score in any LVEF subgroup
Further findings
| Outcome | Adjusted HR (95% CI) | P value | |
|---|---|---|---|
| 12-month all-cause mortality by LVEF group (adjusted) · 12 monthsHF with mildly reduced LVEFvs HF with reduced LVEF | 0.91 (0.59–1.39) | P = 0.73 | |
| 12-month all-cause mortality by LVEF group (adjusted) · 12 monthsHF with preserved LVEFvs HF with reduced LVEF | 0.91 (0.70–1.17) | P = 0.73 | |
| 0.512Adjusted hazard ratio (log scale) |
12-month all-cause mortality by LVEF group (adjusted)
- No significant difference in risk of clinical outcomes across LVEF groups after adjustment
KCCQ clinical summary score change, torsemide vs furosemide, by LVEF subgroup
- No significant difference in any LVEF subgroup
Original publication
Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF. Circ Heart Fail. Published 4 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →